EyePoint Pharmaceuticals (vorher: PSIVIDA) startet durch !! (Seite 208)
eröffnet am 29.01.04 09:28:54 von
neuester Beitrag 23.12.23 12:39:57 von
neuester Beitrag 23.12.23 12:39:57 von
Beiträge: 12.859
ID: 814.884
ID: 814.884
Aufrufe heute: 3
Gesamt: 1.588.556
Gesamt: 1.588.556
Aktive User: 0
ISIN: AU000000PVA7 · WKN: A0Q4DA
1,8250
EUR
-2,93 %
-0,0550 EUR
Letzter Kurs 03.05.18 Tradegate
Neuigkeiten
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 5,0000 | +99.999,00 | |
| 3,0000 | +42,18 | |
| 2,0600 | +24,85 | |
| 451,20 | +20,00 | |
| 8,7400 | +19,73 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 4,0300 | -10,24 | |
| 1,0700 | -10,83 | |
| 3,5200 | -12,87 | |
| 0,6460 | -19,25 | |
| 0,5801 | -19,43 |
Beitrag zu dieser Diskussion schreiben
Feedback
In Australien 7,4% im Plus
2,88 AUD = 2,24€
2,88 AUD = 2,24€
von lucky72 aus dem Alimera Board.
Zitat:
"Na endlich kommt Geld ins Haus!"
May 7, 2013
Alimera Sciences Announces First Patient Treated With Commercially Available ILUVIEN®
ILUVIEN now available in Germany as a new treatment for chronic diabetic macular edema
ATLANTA, May 7, 2013 /PRNewswire/-- Alimera Sciences, Inc., (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that ILUVIEN®, the first sustained release pharmaceutical product for the treatment of chronic diabetic macular edema (DME), is now commercially available in Germany.
In addition, Albert J. Augustin, M.D., professor and chairman of the Department of Ophthalmology, Klinikum Karlsruhe, Karlsruhe, Germany, has treated the world's first patient with the implant injection since the product became commercially available. The patient, a 67-year-old man, was diagnosed with diabetes more than 20 years ago.
"We are honored to be the first hospital to offer this new sustained release treatment to those suffering from vision impairment associated with chronic diabetic macular edema considered insufficiently responsive to available therapies," said Dr. Augustin. "ILUVIEN brings hope to many patients in Germany affected by this sight-robbing disease."
"We are very pleased that patients throughout Germany struggling with this devastating disease can now be treated with ILUVIEN," said Dan Myers, Alimera's president and chief executive officer. "Now chronic DME patients in both Germany and the United Kingdom have a long-acting, sustained release treatment option available to help improve their visual acuity."
http://investor.alimerasciences.com/releasedetail.cfm?Releas…
Zitat:
"Na endlich kommt Geld ins Haus!"
May 7, 2013
Alimera Sciences Announces First Patient Treated With Commercially Available ILUVIEN®
ILUVIEN now available in Germany as a new treatment for chronic diabetic macular edema
ATLANTA, May 7, 2013 /PRNewswire/-- Alimera Sciences, Inc., (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that ILUVIEN®, the first sustained release pharmaceutical product for the treatment of chronic diabetic macular edema (DME), is now commercially available in Germany.
In addition, Albert J. Augustin, M.D., professor and chairman of the Department of Ophthalmology, Klinikum Karlsruhe, Karlsruhe, Germany, has treated the world's first patient with the implant injection since the product became commercially available. The patient, a 67-year-old man, was diagnosed with diabetes more than 20 years ago.
"We are honored to be the first hospital to offer this new sustained release treatment to those suffering from vision impairment associated with chronic diabetic macular edema considered insufficiently responsive to available therapies," said Dr. Augustin. "ILUVIEN brings hope to many patients in Germany affected by this sight-robbing disease."
"We are very pleased that patients throughout Germany struggling with this devastating disease can now be treated with ILUVIEN," said Dan Myers, Alimera's president and chief executive officer. "Now chronic DME patients in both Germany and the United Kingdom have a long-acting, sustained release treatment option available to help improve their visual acuity."
http://investor.alimerasciences.com/releasedetail.cfm?Releas…
Zitat von minadon: http://finance.yahoo.com/news/psivida-corp-announces-commercial-launch-201400401.html
pSivida Corporation’s (ASX: PVA, NASDAQ: PSDV) eye disease treatment, ILUVIEN®, is now commercially available in Germany, marking a major milestone for the company.
Importantly, ILUVIEN® is believed to be the first sustained release pharmaceutical in the European Union to treat chronic diabetic macular edema (DME).
pSivida will be entitled to 20% of the net profits from sales of ILUVIEN® by licensee Alimera Sciences in both Germany and the U.K., where the drug was previously launched.
The first patient has been treated with ILUVIEN® following the commercial launch in Germany.
In the European Union, ILUVIEN® has received marketing authorisation in Austria, France, Germany, Portugal, Spain and the U.K. and is awaiting authorisation in Italy.
Das Geldverdienen geht los, noch langsam... aber dann...
Zitat von speculatitis:http://www.marketwatch.com/story/psivida-corp-announces-new-…
Prima, denke diesmal geht es durch.
wurde jedoch schon hier reingestellt. Doppelt hält besser
wonner schrieb am 01.05.13 14:54:55
Beitrag Nr.10778 (44.547.317)
WATERTOWN, Mass.--(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV - News), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, announced today that the U.S. Food and Drug Administration (FDA) acknowledged receipt of the resubmission of the New Drug Application (NDA) for ILUVIEN® for treatment of chronic diabetic macular edema (DME) and stated that the resubmission was considered a complete, class 2 response to the FDA's November 2011 complete response letter. The new Prescription Drug User Fee Act (PDUFA) goal date is October 17, 2013.....
..."We are very pleased with the FDA's acceptance of the resubmission of the NDA and the new PDUFA date for ILUVIEN," said Dr. Paul Ashton, President and CEO of pSivida Corp. "If the FDA approves ILUVIEN, we would be entitled to an additional $25 million milestone payment from Alimera as well as 20% of net profits, as defined, on any sales in the U.S. by Alimera. We are entitled to the same net profit share on sales of ILUVIEN for DME by Alimera in the EU, where Alimera has already launched in the UK and reported plans to launch in Germany in 2013."
Trading Spotlight
mal sehen ob wir heute an der 3 kratzen. 
allen ein schönes Wochenende!!
allen ein schönes Wochenende!!
pSivida
Another under-$10 stock that's starting to move into range of triggering a major breakout trade is pSivida (PSDV), which develops tiny, sustained-release, drug delivery products designed to deliver drugs at a controlled and steady rate for months or years. This stock has been crazy hot in 2013, with shares up a whopping 100%.
If you take a look at the chart for pSivida, you'll notice that this stock has been trending sideways in a consolidation pattern for the last two months, with shares moving between $1.95 on the downside and around $2.50 on the upside. Shares of PSDV have just started to bounce off its 50-day moving average at $2.20 a share, and that move is quickly pushing the stock within range of triggering a major breakout trade above the upper end of its recent range.
Another under-$10 stock that's starting to move into range of triggering a major breakout trade is pSivida (PSDV), which develops tiny, sustained-release, drug delivery products designed to deliver drugs at a controlled and steady rate for months or years. This stock has been crazy hot in 2013, with shares up a whopping 100%.
If you take a look at the chart for pSivida, you'll notice that this stock has been trending sideways in a consolidation pattern for the last two months, with shares moving between $1.95 on the downside and around $2.50 on the upside. Shares of PSDV have just started to bounce off its 50-day moving average at $2.20 a share, and that move is quickly pushing the stock within range of triggering a major breakout trade above the upper end of its recent range.
Antwort auf Beitrag Nr.: 44.547.523 von binda am 01.05.13 15:41:22
Durchsuchen
